Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 5/20 | 0.53 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503572 | 0.88 | ADAM17 (0.54) | ADAM17ADAM10MMP1 | |
| SCHEMBL1504659 | 0.88 | ADAM17 (0.65) | ADAM17ADAM10MMP1MMP2MMP12 | |
| SCHEMBL1504549 | 0.85 | ADAM17 (0.65) | ADAM17ADAM10MMP1MMP2MMP12 | |
| SCHEMBL17506051 | 0.85 | ADAM17 (0.51) | ADAM17ADAM10MMP1MMP12 | |
| SCHEMBL12077488 | 0.81 | ADAM17 (0.52) | ADAM17ADAM10MMP1MMP2 | |
| SCHEMBL1503669 | 0.80 | ADAM17 (0.79) | ADAM17ADAM10MMP1MMP2 | |
| SCHEMBL12077025 | 0.80 | ADAM17 (0.79) | ADAM17ADAM10MMP1MMP2 | |
| SCHEMBL1503678 | 0.79 | ADAM17 (0.49) | ADAM17 | |
| SCHEMBL1503661 | 0.77 | ADAM17 (0.64) | ADAM17ADAM10MMP1MMP2MMP12 | |
| SCHEMBL1504897 | 0.76 | ADAM17 (0.65) | ADAM17ADAM10MMP1MMP2MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477969-B1 | 4-ALKOXY-N-(2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL)-BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES. | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | claimed |
| US-9266848-B2 | 4-alkoxy-N-(2-hydroxycarbamoyl-2-piperidinyl-ethyl)-benzamide compounds as selective TACE-inhibitors for the treatment of inflammatory diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-02-23 | — | — | US | disclosed |
| EP-2477969-B1 | 4-ALKOXY-N-(2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL)-BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES. | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-20120226033-A1 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-09-06 | — | — | US | disclosed |
| EP-2477969-A1 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Galderma Research & Development (FR) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011033010-A1 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226033-A1 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | TPSAB1, CTSB, TPSB2 | ADAM17 15/4885ADAM10 35/4885MMP1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.